FDA To Provide Celebrex, Iressa Regulatory Updates Before Christmas
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Commissioner Crawford says agency will make "some statement very soon with respect to COX-2 inhibitors in general" and Pfizer's Celebrex "in specific." FDA also will determine whether AstraZeneca's Iressa should be withdrawn or if other regulatory actions are appropriate.